Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer).

BACKGROUND Germ-line mutations in the mismatch-repair genes MLH1, MSH2, MSH6, and PMS2 lead to the development of the Lynch syndrome (hereditary nonpolyposis colorectal cancer), conferring a strong susceptibility to cancer. We assessed the frequency of such mutations in patients with colorectal cancer and examined strategies for molecular screening to identify patients with the syndrome. METHODS Patients with a new diagnosis of colorectal adenocarcinoma at the major hospitals in metropolitan Columbus, Ohio, were eligible for the study. Genotyping of the tumor for microsatellite instability was the primary screening method. Among patients whose screening results were positive for microsatellite instability, we searched for germ-line mutations in the MLH1, MSH2, MSH6, and PMS2 genes with the use of immunohistochemical staining for mismatch-repair proteins, genomic sequencing, and deletion studies. Family members of carriers of the mutations were counseled, and those found to be at risk were offered mutation testing. RESULTS Of 1066 patients enrolled in the study, 208 (19.5 percent) had microsatellite instability, and 23 of these patients had a mutation causing the Lynch syndrome (2.2 percent). Among the 23 probands with the Lynch syndrome, 10 were more than 50 years of age and 5 did not meet the Amsterdam criteria or the Bethesda guidelines for the diagnosis of hereditary nonpolyposis colorectal cancer (including the use of age and family history to identify patients at high risk for the Lynch syndrome). Genotyping for microsatellite instability alone and immunohistochemical analysis alone each failed to identify two probands. In the families of 21 of the probands, 117 persons at risk were tested, and of these, 52 had Lynch syndrome mutations and 65 did not. CONCLUSIONS Routine molecular screening of patients with colorectal adenocarcinoma for the Lynch syndrome identified mutations in patients and their family members that otherwise would not have been detected. These data suggest that the effectiveness of screening with immunohistochemical analysis of the mismatch-repair proteins would be similar to that of the more complex strategy of genotyping for microsatellite instability.

[1]  Hidewaki Nakagawa,et al.  Mismatch Repair Gene PMS2 , 2004, Cancer Research.

[2]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[3]  C. Behling,et al.  Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer. , 2004, Gastroenterology.

[4]  H. Nakagawa,et al.  Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques , 2003, Human mutation.

[5]  Daniel J Sargent,et al.  Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. , 2003, The New England journal of medicine.

[6]  P. Goodfellow,et al.  Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Zwijnenburg,et al.  Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. , 2002, Nucleic acids research.

[8]  Daniel J Sargent,et al.  Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Peltomäki,et al.  Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Leppert,et al.  The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. , 2001, Gastroenterology.

[11]  D. Schaid,et al.  The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. , 2001, American journal of human genetics.

[12]  L. Aaltonen,et al.  Age-related hypermethylation of the 5' region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. , 2001, Cancer research.

[13]  R. Chadwick,et al.  Hereditary and somatic DNA mismatch repair gene mutations in sporadic endometrial carcinoma , 2001, Journal of Medical Genetics.

[14]  S. Antonarakis,et al.  Nomenclature for the description of human sequence variations , 2001, Human Genetics.

[15]  R. Chadwick,et al.  Recurrent germline mutation in MSH2arises frequently de novo , 2000, Journal of medical genetics.

[16]  D. Glavač,et al.  Novel mutations in the homogentisate- 1,2-dioxygenase gene identified in Slovak patients with alkaptonuria , 2000, Journal of medical genetics.

[17]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  L. Aaltonen,et al.  Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. , 2000, Gastroenterology.

[19]  P. Lynch Clinical challenges in management of familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer , 1999, Cancer.

[20]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[21]  G. Deng,et al.  Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. , 1999, Cancer research.

[22]  A. Beaudet Making Genomic Medicine a Reality , 1999 .

[23]  S Srivastava,et al.  A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. , 1998, Cancer research.

[24]  J. Herman,et al.  Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[25]  L. Aaltonen,et al.  Incidence of hereditary nonpolyposis colorectal cancer and the feasibility of molecular screening for the disease. , 1998, The New England journal of medicine.

[26]  C R Scriver,et al.  Proof of “disease causing” mutation , 1998, Human mutation.

[27]  C. Boland,et al.  A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. , 1997, Journal of the National Cancer Institute.

[28]  A. Motulsky Screening for genetic diseases. , 1997, The New England journal of medicine.

[29]  E. Thomson,et al.  Recommendations for Follow-up Care of Individuals With an Inherited Predisposition to Cancer: I. Hereditary Nonpolyposis Colon Cancer , 1997 .

[30]  E. Thomson,et al.  Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. , 1997, JAMA.

[31]  M. Loda,et al.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.

[32]  J. Mecklin,et al.  The International Collaborative Group on HNPCC. , 1994, Anticancer research.

[33]  H T Lynch,et al.  Hereditary Nonpolyposis Colorectal Cancer Patients Replication Errors in Benign and Malignant Tumors from , 2006 .

[34]  K. Kinzler,et al.  Clues to the pathogenesis of familial colorectal cancer. , 1993, Science.

[35]  A. de la Chapelle,et al.  Hereditary Colorectal Cancer , 2010 .